Pharmacology and psychoactive substances – Page 3
-
ResearchBismuth drugs kill bacteria by disrupting metabolism
Scientists throw kitchen sink of omics techniques at understanding complicated response of prevalent human pathogen to bismuth drug
-
-
-
NewsWHO gears up to solve the world’s antivenom crisis
Clinical trials planned to take on scourge of substandard, untested medicines
-
ResearchBrain chemistry hints at how obesity impairs antidepressants
Histamine released in response to obesity or bacterial toxins prevents benefits from SSRIs – and that drugs that target these inflammatory signals may restore them
-
ResearchNew theory for why lithium helps bipolar patients
Molecular insight could help researchers design mood stabilisers with fewer side effects
-
ResearchNicotine degrading enzyme could help smokers quit
Enzyme removes nicotine from blood before it can stimulate brain’s reward system
-
ResearchTagging drugs with heavy hydrogen made as easy as flicking a light switch
Photoredox reaction simplifies metabolism studies by swapping hydrogen for deuterium or tritium
-
ResearchHow total synthesis is creating antibiotics
Macrolide synthesis could reinvigorate the antibiotic pipeline
-
FeatureHow ketamine could help treat severe depression
Nina Notman looks at how the party drug ketamine may hold the key to treating patients with severe depression
-
FeatureDeal or no deal?
Clare Sansom highlights recent changes in the landscape of pharma company collaborations and acquisitions
-
ResearchMolecular structure is teixobactin’s pièce de résistance
Study builds scientists’ arsenal against drug-resistant superbugs
-
ResearchCrystal structure lifts lid on LSD’s secrets
Structure of hallucinogen bound to a human serotonin receptor could explain LSD’s potent and long-lasting effects
-
FeatureNew opioid drugs
Creating powerful new painkillers is a constant battle against side-effects – particularly addictions. James Mitchell Crow reports
-
OpinionRestarting the mental health pipeline
The lack of UK investment in new drugs for mental health disorders is a problem – but the tide may be about to turn
-
CareersThe trials and tribulations of drug discovery
The many pitfalls medicinal chemists face when creating a new drug
-
-
OpinionWe need a global plan to beat resistance
We all need to do our bit and act for the common good if we’re going to protect antibiotics
-
OpinionCan we wait for e-cigarette trials?
Safety data is needed but is not a reason to ignore vaping now, says Thomas Hartung
-
OpinionRethinking risk assessment
Toxicologists must embrace better ways of accounting for low dose effects, argue Annamaria Colacci and Nicole Kleinstreuer